Verdiva cans mid-stage obesity trial of GLP-1 pill, citing 'market evolution'
Verdiva Bio, one of the best-funded private biotechs seeking to get into the lucrative obesity drug market, has terminated one of the Phase 2 trials of its lead asset, a spokesperson ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.